Skip to main content

Articles By Robert Chao, MD

covid coronavirus virus

Spondyloarthritis and COVID-19

By Robert Chao, MD
15 June 2022

There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question. 

Read Article
Back Pain

JAKi for nonradiographic axSpA

By Robert Chao, MD
01 June 2022

One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. Furthermore, the question of the utility of JAK inhibitors for the treatment of axial spondyloarthritis has been on the rise. 

Read Article
heel enthesitis spur calcaneal

The Enthesitis Challenge in Psoriatic Arthritis

By Robert Chao, MD
06 April 2022

A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do! 

Read Article
switch.jpg

Monitoring Infliximab Drug Levels Improves Efficacy

By Robert Chao, MD
08 December 2021

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?

Read Article
pso.arm_.JPG

Risankizumab for Active Psoriatic Arthritis

By Robert Chao, MD
26 November 2021

The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis.

Read Article
switch.jpg

Monitoring Infliximab Drug Levels Improves Efficacy

By Robert Chao, MD
09 November 2021

Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?

Read Article
pso.arm_.JPG

Risankizumab for Active Psoriatic Arthritis

By Robert Chao, MD
06 November 2021

The arsenal of therapeutics for psoriatic arthritis continues to increase. Risankizumab is an IL-23 inhibitor to the p19 subunit, currently being investigated for treatment of psoriatic arthritis.

Read Article
PSORIASIS.LH_.jpg

ICYMI: Psoriatic Disease Management - RNL 2021 Highlights

By Robert Chao, MD
08 July 2021

This year’s coverage of psoriatic arthritis was once again, both exciting and informative. Topics included an overview of the latest therapeutic options, an excellent discussion on psoriasis specifically, and the epidemiology of psoriatic arthritis. 

Read Article
pregnant, pregnancy, mother, fertility

Current approach to lupus and pregnancy

By Robert Chao, MD
14 June 2021

All of us are extremely cautious with lupus patients when it comes to pregnancy. Presentation 6888 (Common issues in pregnancy management in lupus and anti-phospholipid syndrome by Dr. Rebecca Fischer-Betz) was an excellent overview of our current approach to lupus and pregnancy. 

Read Article
unhappy%20patient.jpg

How do we personalize psoriatic arthritis treatment?

By Robert Chao, MD
07 June 2021

It seems like every conference we are presented with data on the newest biologic for treatment of psoriatic arthritis, but the question is, do we need it?

Read Article
×